dc.contributor.author | Fankhauser, Christian Daniel | |
dc.contributor.author | Oldenburg, Jan | |
dc.contributor.author | Albers, Peter | |
dc.contributor.author | Algaba, Ferran | |
dc.contributor.author | Bokemeyer, Carsten | |
dc.contributor.author | Boormans, Joost L. | |
dc.contributor.author | Fischer, Stefanie | |
dc.contributor.author | Fizazi, Karim | |
dc.contributor.author | Gremmels, Hendrik | |
dc.contributor.author | Mayor de Castro, Javier | |
dc.contributor.author | Janisch, Florian | |
dc.contributor.author | Muilwijk, Tim | |
dc.contributor.author | Leao, Ricardo | |
dc.contributor.author | Nicol, David | |
dc.contributor.author | Nicolai, Nicola | |
dc.contributor.author | Tandstad, Torgrim | |
dc.contributor.author | del Pilar Laguna Pes, Maria | |
dc.date.accessioned | 2021-08-02T08:52:49Z | |
dc.date.available | 2021-08-02T08:52:49Z | |
dc.date.issued | 2021 | en_US |
dc.identifier.citation | Fankhauser, C. D., Oldenburg, J., Albers, P., Algaba, F., Bokemeyer, C., Boormans, J. L. ... del Pilar Laguna Pes, M. (2021). Recommendations to balance benefits and risks of thromboprophylaxis and to avoid central venous-access devices during first-line chemotherapy in men with metastatic germ cell tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021. European Urology, 80(1), 4-6. https://dx.doi.org/10.1016/j.eururo.2021.02.032 | en_US |
dc.identifier.issn | 0302-2838 | |
dc.identifier.issn | 1873-7560 | |
dc.identifier.uri | https://dx.doi.org/10.1016/j.eururo.2021.02.032 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/7641 | |
dc.description.abstract | Recent randomized controlled trials have assessed the risksand benefits of thromboprophylaxis in ambulatory cancerpatients receiving chemotherapy and reported a relativerisk reduction of 30–60% in venous thromboembolic events(VTEs) but a doubling of bleeding risk [1–4]. Based on theseresults, the most recent American Society of ClinicalOncology clinical practice guideline update recommendsthromboprophylaxis with apixaban, rivaroxaban, or low-molecular–weight heparin (LMWH) for cancer patientswith a high risk of VTE and low risk of bleeding [5]. Patientswith metastatic germ-cell tumor (mGCT) were under-represented in all trials and thus it is not clear whether thisrecommendation applies to this group, although retrospec-tive data suggests similar efficacy of VTE prophylaxis. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier | en_US |
dc.rights | info:eu-repo/semantics/embargoedAccess | en_US |
dc.subject | Balance Benefits | en_US |
dc.subject | Risks of Thromboprophylaxis | en_US |
dc.subject | Metastatic Germ Cell Tumors | en_US |
dc.subject | European Association Of Urology Testicular Cancer Panel Position in 2021 | en_US |
dc.title | Recommendations to balance benefits and risks of thromboprophylaxis and to avoid central venous-access devices during first-line chemotherapy in men with metastatic germ cell tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021 | en_US |
dc.type | editorial | en_US |
dc.relation.ispartof | European Urology | en_US |
dc.department | İstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Üroloji Ana Bilim Dalı | en_US |
dc.authorid | 0000-0003-0906-4417 | en_US |
dc.identifier.volume | 80 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.startpage | 4 | en_US |
dc.identifier.endpage | 6 | en_US |
dc.relation.publicationcategory | Diğer | en_US |
dc.identifier.doi | 10.1016/j.eururo.2021.02.032 | en_US |
dc.identifier.wosquality | Q1 | en_US |
dc.identifier.scopusquality | Q1 | en_US |